Hampton, UK – 03 December 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of John Dwyer to the Company’s Board of Directors as a Non-Executive Director.
John spent over 20 years as partner at PwC UK, where he led the Global Deals Business and sat on the Executive Board as Head of Deals with responsibility for the TS, Restructuring, Corporate Finance and Forensics businesses.
Since leaving PwC in 2017, John has taken up several non-executive and chair positions at Private Equity portfolio companies, as well as supporting financial transactions at firms like Pigsback.com and Exponent. John is currently Chairman of both C&N Sporting Risk, a tech-based sports business, and Irish middle-market PE firm Renatus.
Jonny Ohlson, Executive Chairman of Touchlight, commented: “John brings more than 30 years of distinguished experience in leadership, commercial strategy, finance and operations. We are pleased that he has decided to join our board and confident that his support will help Touchlight achieve our long-term objectives.”
Commenting on his appointment, John Dwyer said: “I’m delighted to join the Board of Directors of such an innovative company as Touchlight. With nucleic acid vaccines growing in importance by the day, this might be the most exciting time to join a company in this field. I believe that doggybone DNA has an immense potential and look forward to leveraging my experience to assist as Touchlight advances to the next level.”
- ENDS -
Notes to Editors
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone” or dbDNA™.
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
Jonny Ohlson, CEO
At Instinctif Partners
Tim Watson / Agnes Stephens / Katie Duffell